Psyence Biomedical Advances in Phase IIb Psilocybin Clinical Trial

An announcement from Psyence Biomedical ( (PBM) ) is now available.

Psyence Biomedical has announced significant progress in its Phase IIb clinical trial, which explores the use of natural psilocybin with psychotherapy as a treatment for Adjustment Disorder in patients with life-limiting cancer diagnoses. The trial, conducted at sites in Australia, is supported by ACTioN, a clinical trial site management organization, to enhance patient recruitment and retention. Psyence Biomedical aims to commence patient randomization by January and expects to report topline results in the latter half of 2025, reflecting its commitment to innovative mental health solutions in Palliative Care.

More about Psyence Biomedical

Psyence Biomedical Ltd. (Nasdaq: PBM) is a pioneering life science biotechnology company specializing in the development of nature-derived psilocybin-based psychedelic medicines. The company focuses on addressing unmet mental health needs, particularly in the context of Palliative Care, by developing safe, effective, and regulatory-approved psychedelic therapeutics.

YTD Price Performance: -99.75%

Average Trading Volume: 770,267

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.48M

For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.